| 摘要 |
<p>This invention generally relates to a novel use of IL-1beta-ligand/IL-1 receptor disrupting compounds (herein referred to also as "IL-1beta Compounds") in a therapy preventing manifestations and especially complications leading to subsequent damages, such as vaso-occlusion, in individuals being threatened by sickle cell disease (that is, especially homozygous HbS gene carriers, heterozygotes with sickle-beta-thalassemia with an SCD supporting combination of HbS gene and beta-thal gene, an individual with one sickle cell gene and one null alleleor an individual with hemoglobin SC disease).</p> |
